36.71

1.09% 0.395

After Hours: 36.71

Tyra Biosciences Inc (TYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Tyra Biosciences Inc stock is traded at $36.71, with a volume of 757.30K. It is up +1.09% in the last 24 hours and up +6.41% over the past month. Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Previous Close:

$36.31

Open:

$37.61

24h Volume:

757.30K

Relative Volume:

0.84

Market Cap:

$1.98B

Revenue:

Net Income/Loss:

$-119.95M

P/E Ratio:

-18.24

EPS:

-2.0123

Net Cash Flow:

$-95.28M

1W Performance:

-3.52%

1M Performance:

+6.41%

6M Performance:

+192.74%

1Y Performance:

+256.06%

1-Day Range:

$36.68

$38.27

1-Week Range:

$34.85

$39.15

52-Week Range:

$6.42

$39.15

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name

Tyra Biosciences Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(619) 728-4760

Address

2656 STATE STREET, CARLSBAD

Employee

Twitter

Next Earnings Date

2025-03-26

Latest SEC Filings

TYRA's Discussions on Twitter

Compare TYRA vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TYRA Tyra Biosciences Inc	36.71	1.96B	0	-119.95M	-95.28M	-2.0123
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Cantor Fitzgerald	Overweight
Feb-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight
Sep-03-25	Initiated	Raymond James	Strong Buy
May-21-25	Resumed	Piper Sandler	Overweight
Jan-07-25	Initiated	UBS	Buy
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy
Aug-15-24	Initiated	Piper Sandler	Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Jun-30-23	Initiated	Wedbush	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Jun-23-22	Initiated	H.C. Wainwright	Buy
Mar-08-22	Upgrade	Jefferies	Hold → Buy
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	BofA Securities	Buy
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	Jefferies	Buy

View All

Tyra Biosciences Inc Stock (TYRA) Latest News

Mar 25, 2026

[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com

Mar 25, 2026

Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com

Mar 25, 2026

Mar 24, 2026

Dabo gratinib designation honors key Tyra Biosciences executives - Traders Union

Mar 24, 2026

Mar 23, 2026

Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.5%Should You Sell? - MarketBeat

Mar 23, 2026

Mar 22, 2026

Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance - Sahm

Mar 22, 2026

Best Growth Stocks To Follow Today – March 20th - Defense World

Mar 22, 2026

Piper Sandler Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $56.00 - Defense World

Mar 22, 2026

Mar 21, 2026

Technical Reactions to TYRA Trends in Macro Strategies - Stock Traders Daily

Mar 21, 2026

Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook - Sahm

Mar 21, 2026

Mar 20, 2026

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position - AOL.com

Mar 20, 2026

Boone Capital Invests in Tyra Biosciences: $10.48M Stake AcquiredNews and Statistics - IndexBox

Mar 20, 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool

Mar 20, 2026

Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat

Mar 20, 2026

Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $56 - 富途牛牛

Mar 20, 2026

Mar 19, 2026

Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Mar 19, 2026

Mar 18, 2026

Forecast Cut: Can Tyra Biosciences Inc continue delivering strong returnsIPO Watch & Smart Swing Trading Techniques - baoquankhu1.vn

Mar 18, 2026

Hedge Fund Bets: Is Tyra Biosciences Inc a strong candidate for buy and holdQuarterly Portfolio Report & Smart Allocation Stock Tips - baoquankhu1.vn

Mar 18, 2026

Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation - MSN

Mar 18, 2026

Cantor Fitzgerald initiates coverage of Tyra Biosciences (TYRA) with overweight recommendation - MSN

Mar 18, 2026

Mar 17, 2026

Tyra Biosciences (TYRA) CFO adds 1,376 shares via employee stock plan - Stock Titan

Mar 17, 2026

Tyra Biosciences (TYRA) CEO adds 1,463 ESPP shares, holdings reach 1.36M - Stock Titan

Mar 17, 2026

Ideas Watch: Is Tyra Biosciences Incs ROE strong enoughMarket Trend Report & Smart Money Movement Tracker - baoquankhu1.vn

Mar 17, 2026